Premium
Peritonitis after percutaneous endoscopic gastrojejunostomy for levodopa–carbidopa intestinal gel treatment despite concomitant use of gastropexy
Author(s) -
Tsuboi Takashi,
Watanabe Hirohisa,
Funasaka Kouhei,
Takebayashi Mikiko,
Miyata Kazushi,
Katsuno Masahisa
Publication year - 2018
Publication title -
neurology and clinical neuroscience
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2049-4173
DOI - 10.1111/ncn3.12183
Subject(s) - medicine , gastropexy , concomitant , percutaneous endoscopic gastrostomy , carbidopa , peg ratio , surgery , peritonitis , fibrous joint , percutaneous , levodopa , gastroenterology , stomach , disease , parkinson's disease , finance , economics
A 58‐year‐old man with Parkinson's disease experienced peritonitis after percutaneous endoscopic gastrojejunostomy ( PEG ‐J) for levodopa–carbidopa intestinal gel treatment despite concomitant use of gastropexy. Although gastropexy reduces complications including peritonitis, clinicians should consider structural characteristics of PEG ‐J devices and patients’ anatomical differences. We recommend that suture threads are removed 2–4 weeks after PEG ‐J and that the PEG ‐J tube length outside the body is routinely recorded to assess tube dislocation.